Physician profile
Jaime Jimenez
NPI 1932102951
$12,638.65
in general payments reported to CMS, 2019-2025
22 companies · $959 in 2025
The $959 reported for 2025 was more than what 76% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,758 · 2020: $2,982 · 2021: $3,793 · 2022: $1,218 · 2023: $905 · 2024: $1,024 · 2025: $959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,769 · Education: $89.00 · Entertainment: $29.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,769.40 |
| Education | $89.00 |
| Entertainment | $29.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $4,740.77 | 2019-2024 | Yutiq, Iluvien |
| Novartis Pharmaceuticals Corporation | $3,300.25 | 2019-2021 | |
| Abbvie INC. | $1,449.34 | 2022-2025 | |
| Apellis Pharmaceuticals, INC. | $621.99 | 2022-2025 | Syfovre |
| Allergan, INC. | $499.59 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $325.12 | 2022-2025 | Stellaris, Xipere |
| Genentech USA, INC. | $256.22 | 2019-2024 | Vabysmo, Susvimo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $251.90 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $184.83 | 2025 | Iluvien, Purified Cortrophin Gel, Yutiq |
| Coherus Oncology, INC. | $169.42 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $166.61 | 2019-2024 | Eylea Hd, Eylea |
| Mallinckrodt Hospital Products INC. | $137.35 | 2025 | Acthar |
| Alcon Vision LLC | $107.71 | 2019-2024 | Rocklatan |
| Glaukos Corporation | $74.21 | 2020-2023 | Istent Infinite Trabecular Micro-Bypass System Model Is3, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3 |
| Aerie Pharmaceuticals, INC. | $66.09 | 2019-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $65.38 | 2020 | |
| Astellas Pharma US INC | $59.73 | 2023-2024 | Izervay |
| Topcon Healthcare Solutions, INC. | $41.81 | 2022 | |
| Sandoz INC. | $38.59 | 2024 | Cimerli |
| Harrow Eye, LLC | $36.15 | 2025 | Iheezo |
| Opsens INC. | $29.56 | 2023 | Optowire |
| Eyepoint US, INC. | $16.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Jimenez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.